
The US Food and Drug Administration has issued a draft guidance, “Early-Phase IND Protocol Recommendations for Solid Tumors,” setting out how sponsors and clinical investigators should design first-in-human and other early-phase cancer trials under an Investigational New Drug application (IND). The Federal Register notice of availability was published on 12 November 2026, and comments are due by 11 January 2027 under docket FDA-2026-D-13432. Academic sponsor-investigators and cancer-centre research offices are directly affected.
What happened
The guidance was prepared by FDA’s Oncology Center of Excellence with the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), and is dated November 2026. The Federal Register notice, published on 12 November, describes it as recommendations for early-phase trials, including first-in-human protocols and protocols for drugs and biologics with limited human experience, submitted to CDER’s Office of Oncologic Diseases or CBER’s Office of Clinical Evaluation. RAPS reported the release on 11 November 2026.
FDA lists the guidance among its actions under Operation TrialBlazer, an HHS initiative to accelerate and modernize clinical development from the IND phase through late-stage pivotal trials. The draft states that its recommendations draw on common issues FDA has identified while reviewing early-phase INDs.
Key details
| Item | Detail |
|---|---|
| Document | Draft guidance for industry, nonbinding, “Draft: Not for Implementation” |
| Issuing office | Oncology Center of Excellence, with CDER and CBER |
| Federal Register notice | 12 November 2026 (document 2026-22970) |
| Docket | FDA-2026-D-13432, comments through regulations.gov |
| Comment deadline | 11 January 2027 |
| Scope | Solid tumors only; hematologic malignancies are not covered |
The draft covers eligibility criteria, dose-escalation design, dose-limiting toxicity criteria, expansion cohorts, assessment of activity, selection of the recommended Phase 2 dose, individual-patient stopping rules, companion diagnostics, administration relative to food, and pharmacokinetic, ECG and immunogenicity sampling. Recommendations that stand out for protocol authors:
- Eligibility. Unnecessarily restrictive criteria “may slow patient accrual, limit patient access to early-phase trials, and lead to trial results that have limited applicability.” In general, protocols should not impose upper age limits, and FDA generally does not recommend time-based washout periods unless scientifically justified. Informed consent should name any available therapies shown to prolong overall survival.
- Study objectives. For a first-in-human trial, the primary objectives should be safety and tolerability; dose identification, pharmacokinetics, pharmacodynamics and preliminary activity can be secondary or exploratory.
- Dose escalation. A rule-based or model-based design should be prespecified. For model-based designs such as the Bayesian logistic regression model, FDA asks for a description of the data supporting the model’s assumptions and simulation studies showing a low probability of selecting an excessively toxic dose.
- Expansion cohorts. The statistical analysis plan should justify the maximum sample size and include stopping rules for excessive toxicity or lack of activity. If a tumor-specific signal emerges, FDA prefers a new IND to the responsible review division rather than expanding an exploratory cohort beyond 40 patients under the early-phase IND.
- Activity assessment. Single-arm trials “do not adequately characterize endpoints, such as overall survival or progression-free survival”; a randomized study is generally necessary for time-to-event endpoints.
- Dose selection. The recommended Phase 2 dose should rest on the totality of pharmacokinetic, safety and efficacy information rather than the maximum tolerated dose alone, with late toxicity considered.
- Companion diagnostics. If biomarker-based selection is essential to safe and effective use, FDA recommends consulting the Center for Devices and Radiological Health early.
Background and context
The draft builds on earlier FDA oncology guidances that it cites, including the March 2022 guidance on expansion cohorts in first-in-human trials, the August 2024 guidance on optimizing dosage in oncology, and a series of cancer trial eligibility guidances, several of them dated July 2026. It follows other TrialBlazer early-stage actions, including the Expedited IND Pilot Program, which FDA describes as a way to let sponsors partner with qualified research institutions and have components of an IND reviewed on a rolling basis.
As with all FDA guidance, the document does not create legally enforceable responsibilities. Where it cites regulations, such as 21 CFR 312.22 on the agency’s primary objective of protecting subjects’ safety and rights, or 21 CFR 50.25 on informed consent elements, those requirements apply independently.
Reaction
RAPS summarized the draft as stressing broader eligibility, safety and tolerability as the primary objective of first-in-human trials, limits on exposure in expansion cohorts and the point that single-arm studies cannot adequately characterize survival endpoints. Formal responses from sponsors, cancer centres and professional societies will appear in the public docket as comments are filed.
What it means for researchers, universities and research offices
Institutions that act as sponsor-investigators on an IND for a first-in-human solid-tumor study should compare their protocol templates with the draft now, even though it is not binding. Points to check include upper age limits, washout periods and brain-metastasis or viral-infection exclusions that lack a stated justification, whether the dose-escalation design is prespecified with supporting simulations, and whether expansion cohorts carry a justified maximum sample size and stopping rules.
Institutional review boards reviewing phase 1 trials will see the draft’s consent expectations: informed consent should state whether alternatives known to confer clinical benefit exist, and re-consent is recommended when patients continue treatment beyond radiographic progression and alternative therapies exist. Research offices can use the draft when preparing a pre-IND meeting request, which FDA encourages for unique disease settings and therapies, and when reviewing dose-escalation design choices. Cancer centres that plan to rely on early-phase data and expansion cohorts to support a marketing application are told to meet the review division as early as possible. For wider context see casrai’s guide to FDA guidance documents.
What happens next
Comments close on 11 January 2027. FDA says it considers comments received by that date before it begins work on the final version. Comments are submitted at regulations.gov under docket FDA-2026-D-13432 and are posted publicly, so confidential information should not be included; written submissions go to the Dockets Management Staff at FDA’s Rockville, Maryland address. Questions about the draft can be sent to the Oncology Center of Excellence at [email protected].
Sources
- FDA, Early-Phase IND Protocol Recommendations for Solid Tumors, draft guidance, November 2026
- FDA, FDA actions to accelerate and modernize early and late-stage clinical development (Operation TrialBlazer)
- Federal Register, Notice of availability, 12 November 2026
- RAPS, FDA issues draft guidance on early-phase IND studies for solid tumors, 11 November 2026







